2000December 21, 2000Maxygen Delivers Lead Agriculture Development Candidate December 21, 2000Maxygen Takes Additional Product Candidate into Development December 7, 2000Maxygen and Integrated Genomics Announce Collaboration November 20, 2000Maxygen and Hercules Announce Bioprocess Alliance Focusing on Specific Specialty Chemicals November 14, 2000Maxygen Reports 2000 Third Quarter Financial Results October 25, 2000Maxygen Announces Strategic Agreement to Develop New Bulk Chemical Bioprocesses with Chevron October 18, 2000Maxygen Awarded Broad Gene Shuffling Patent October 4, 2000Maxygen Announces Two Year Extension of Collaboration with Pioneer Hi-Bred September 19, 2000Maxygen and H. Lundbeck A/S Enter into Research and Development Agreement September 15, 2000Maxygen and Shearwater Enter Into Strategic Protein Pharmaceutical Alliance September 15, 2000Maxygen and The Scripps Research Institute Establish Collaboration for Development of Novel HIV Therapies and Vaccines September 13, 2000Maxygen Awarded Broad Patent Expanding its Leadership Position in Directed Molecular Evolution September 13, 2000Maxygen Announces Follow-On Bioprocess Collaboration with Pfizer and Advancement of Product Candidate August 22, 2000Maxygen Announces Issuance of Patent Covering Preparation of Improved Vectors August 10, 2000Maxygen Completes Acquisition of ProFound Pharma A/S August 8, 2000Maxygen Reports 2000 Second Quarter Financial Results July 26, 2000Maxygen Enters Into Development Program for Allergy Therapeutics with The Karolinska Institute June 13, 2000Maxygen Announces Advancement of Additional Product Candidate June 12, 2000Maxygen and DSM Achieve Research Milestone in Chemical Bioprocess Development Program May 9, 2000Maxygen Reports 2000 First Quarter Financial Results May 5, 2000Maxygen Announces Promotion of New President April 27, 2000Maxygen Initiates Arbitration Against Energy Biosystems April 12, 2000Maxygen to Acquire ProFound Pharma A/S to Expand its Position in Protein Pharmaceuticals March 21, 2000Maxygen Prices Follow-On Offering of 1,5000,000 Shares of Common Stock February 28, 2000Maxygen Announces Cooperative Research and Development Agreement with The National Cancer Institute for Novel Protein Pharmaceuticals February 22, 2000Maxygen Reports Fourth Quarter and Year End 1999 Financial Results February 10, 2000Maxygen Appoints George Poste to its Board of Directors and Announces Addition to Senior Management February 10, 2000Maxygen Announces Bioprocess Development Collaboration with Rio Tinto
Return to News
|
